- Take the Leukemia Quiz!
- 15 Cancer Symptoms Women Ignore Slideshow
- Cancer Symptoms Men Ignore Slideshow
What Is Campath (alemtuzumab)?
Common side effects of Campath include:
- low blood cell counts,
- infusion reactions,
- cytomegalovirus (CMV) and other infections,
- and chills.
Other side effects of Campath include:
Campath may interact with other drugs. Campath drug interaction studies have not been conducted. Campath may cross the placental barrier and may be excreted in breast milk. Campath has not been studied in pregnant women or nursing mothers. It should be given to a pregnant or breastfeeding woman only if clearly needed.
What are the important side effects of Campath (alemtuzumab)?
Common side effects include:
- Low blood cell counts
- Infusion reactions
- Cytomegalovirus (CMV) and other infections
Other side effects include:
Campath (alemtuzumab) side effects list for healthcare professionals
The following adverse reactions are discussed in greater detail in other sections of the label:
- Infusion Reactions
The most common adverse reactions with Campath are:
- infusion reactions (pyrexia, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea),
- cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia),
- infections (CMV viremia, CMV infection, other infections),
- gastrointestinal symptoms (nausea, emesis, abdominal pain),
- and neurological symptoms (insomnia, anxiety).
The most common serious adverse reactions are:
- infusion reactions,
- and immunosuppression/infections.
Clinical Trials Experience
- Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
- The data below reflect exposure to Campath in 296 patients with CLL of whom 147 were previously untreated and 149 received at least 2 prior chemotherapy regimens.
- The median duration of exposure was 11.7 weeks for previously untreated patients and 8 weeks for previously treated patients.
- Severe lymphopenia and a rapid and sustained decrease in lymphocyte subsets occurred in previously untreated and previously treated patients following administration of Campath.
- In previously untreated patients, the median CD4+ was 0 cells/µL at one month after treatment and 238 cells/µL [25%- 75% interquartile range 115 to 418 cells/µL at 6 months post treatment.
- In previously untreated patients, the incidence of Grade 3 or 4 neutropenia was 42% with a median time to onset of 31 days and a median duration of 37 days.
- In previously treated patients, the incidence of Grade 3 or 4 neutropenia was 64% with a median duration of 28 days.
- Ten percent of previously untreated patients and 17% of previously treated patients received granulocyte colony-stimulating factors.
- In previously untreated patients, the incidence of Grade 3 or 4 anemia was 12% with a median time to onset of 31 days and a median duration of 8 days.
- In previously treated patients, the incidence of Grade 3 or 4 anemia was 38%.
- Seventeen percent of previously untreated patients and 66% of previously treated patients received either erythropoiesis stimulating agents, transfusions or both.
- In previously untreated patients, the incidence of Grade 3 or 4 thrombocytopenia was 14% with a median time to onset of 9 days and a median duration of 14 days.
- In previously treated patients, the incidence of Grade 3 or 4 thrombocytopenia was 52% with a median duration of 21 days.
- Autoimmune thrombocytopenia was reported in 2% of previously treated patients with one fatality.
- Infusion reactions, which included pyrexia, chills, hypotension, urticaria, and dyspnea, were common.
- Grade 3 and 4 pyrexia and/or chills occurred in approximately 10% of previously untreated patients and in approximately 35% of previously treated patients.
- The occurrence of infusion reactions was greatest during the initial week of treatment and decreased with subsequent doses of Campath.
- All patients were pretreated with antipyretics and antihistamines; additionally, 43% of previously untreated patients received glucocorticoid pre-treatment.
- In the study of previously untreated patients, patients were tested weekly for CMV using a PCR assay from initiation through completion of therapy, and every 2 weeks for the first 2 months following therapy.
- CMV infection occurred in 16% (23/147) of previously untreated patients; approximately onethird of these infections were serious or life threatening.
- In studies of previously treated patients in which routine CMV surveillance was not required, CMV infection was documented in 6% (9/149) of patients; nearly all of these infections were serious or life-threatening.
- Other infections were reported in approximately 50% of patients across all studies. Grade 3 to 5 sepsis ranged from 3% to 10% across studies and was higher in previously treated patients.
- Grade 3 to 4 febrile neutropenia ranged from 5% to 10% across studies and was higher in previously treated patients.
- Infection-related fatalities occurred in 2% of previously untreated patients and 16% of previously treated patients.
- There were 198 episodes of other infection in 109 previously untreated patients; 16% were bacterial, 7% were fungal, 4% were other viral, and in 73% the organism was not identified.
Cardiac dysrhythmias occurred in approximately 14% of previously untreated patients. The majority were tachycardias and were temporally associated with infusion; dysrhythmias were Grade 3 or 4 in 1% of patients.
Previously Untreated Patients
- Table 1 contains selected adverse reactions observed in 294 patients randomized (1:1) to receive Campath or chlorambucil as first line therapy for B-CLL.
- Campath was administered at a dose of 30 mg intravenously three times weekly for up to 12 weeks.
- The median duration of therapy was 11.7 weeks with a median weekly dose of 82 mg (25-75% interquartile range: 69-90 mg).
|All Grades† %||Grades 3-4 %||All Grades %||Grades 3-4 %|
|Blood and Lymphatic System Disorders||Lymphopenia||97||97||9||1|
|General Disorders and Administration Site Conditions||Pyrexia||69||10||11||1|
|Infections and Infestations||CMV viremia‡||55||4||8||0|
|Skin and Subcutaneous Tissue Disorders||Urticaria||16||2||1||0|
|Nervous System Disorders||Headache||14||1||8||0|
|Respiratory, Thoracic and Mediastinal Disorders||Dyspnea||14||4||7||3|
|Adverse reactions occurring at a higher relative frequency in the Campath arm|
†NCI CTC version 2.0 for adverse reactions; NCI CTCAE version 3.0 for laboratory values
‡CMV viremia (without evidence of symptoms) includes both cases of single PCR positive test results and of confirmed CMV viremia (≥2 occasions in consecutive samples 1 week apart). For the latter, ganciclovir (or equivalent) was initiated per protocol.
Previously Treated Patients
Additional safety information was obtained from 3 single arm studies of 149 previously treated patients with CLL administered 30 mg Campath intravenously three times weekly for 4 to 12 weeks (median cumulative dose 673 mg [range 2-1106 mg]; median duration of therapy 8.0 weeks).
Adverse reactions in these studies not listed in Table 1 that occurred at an incidence rate of >5% were:
As with all therapeutic proteins, there is potential for immunogenicity.
Using an ELISA assay, antihuman antibodies (HAHA) were detected in 11 of 133 (8.3%) previously untreated patients.
In addition, two patients were weakly positive for neutralizing activity.
Limited data suggest that the anti-Campath antibodies did not adversely affect tumor response. Four of 211 (1.9%) previously treated patients were found to have antibodies to Campath following treatment.
The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including:
- assay methodology,
- sample handling,
- timing of sample collection,
- concomitant medications,
- and underlying disease.
For these reasons, comparison of the incidence of antibodies to Campath with the incidence of antibodies to other products may be misleading.
The following adverse reactions have been identified during post-approval use of alemtuzumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Fatal Infusion Reactions
Gastrointestinal: Acute acalculous cholecystitis
Immune disorders: Goodpasture's syndrome, Graves' disease, aplastic anemia, Guillain Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, serum sickness, fatal transfusion associated graft versus host disease.
Metabolic: tumor lysis syndrome.
Neurologic: optic neuropathy.
Multimedia: Slideshows, Images & Quizzes
Understanding Cancer: Metastasis, Stages of Cancer, and More
Learn the basics about cancer including types, causes, how it spreads, symptoms and signs, stages and treatment options. Read...
Cancer: Cancer 'Remedies' That Don't Work
You may have read about an all-natural cure for cancer. While many therapies are helpful, some aren't worth your time or money....
Cancer: Guide to Leukemia
Learn about the common types and stages of leukemia, who gets it, symptoms, tests, treatments, and more. People with blood cancer...
Cancer-Fighting Foods: Resveratrol, Green Tea, and More
Experts have praised certain foods for their ability to reduce cancer risks. Learn which foods and eating strategies may help...
Signs of Cancer in Women: Symptoms You Can't Ignore
Colon and stomach cancer symptoms can surprise women but can be treated if detected early. Learn about breast cancer signs and...
Cancer: Does This Cause Cancer?
Everything gives you cancer, right? Not really. WebMD's slide show tells you about the research into cancer and cell phones,...
Cancer: Symptoms of Common Cancers in Men
Can men get breast cancer? Cancer symptoms men need to watch out for include skin changes, difficulty swallowing, rapid weight...
What do you know about leukemia? Did you know there are different types? What are the symptoms? Take the Leukemia Quiz and test...
Top 10 Cancers Quiz
Take this quiz to learn the causes of cancer. Get the facts about the causes, symptoms, and treatments for the world's most...
Related Disease Conditions
Leukemia is a type of cancer of the blood cells in which the growth and development of the blood cells are abnormal. Strictly speaking, leukemia should refer only to cancer of the white blood cells (the leukocytes) but in practice it can apply to malignancy of any cellular element in the blood or bone marrow, as in red cell leukemia (erythroleukemia).
Is Cancer Contagious?
Cancer is an abnormal growth of cells. A variety of parasites and viruses have been linked to various cancers. Cancer may metastasize, spreading from its original location to other organs. If you have cancer, you should seek medical care immediately if you experience high fever, shortness of breath, intense headaches, vomiting blood or passing blood rectally, chest pain or moderate to severe weakness, passing out (fainting), mental status changes, or seizures.
Childhood Acute Lymphoblastic Leukemia (ALL)
Childhood acute lymphoblastic leukemia is the most common type of cancer in children. Symptoms and signs include fever, easy bruising, bone or joint pain, weakness, loss of appetite, and painless lumps in the neck, underarm, stomach, or groin. Treatment depends upon staging and may include chemotherapy, radiation, or stem cell transplant.
Treatment & Diagnosis
- Mind-Body Medicine for Cancer Patients
- Bone Cancer
- Cancer: Confronting Cancer with Humor
- Cancer and Green Tea
- Cancer Survival and Attitude with Hamilton Jordan
- Cancer Treatment: Writing to Heal with Margie Davis
- Cancer Pain Management with Ann Reiner
- Cancer Patients Need Proper Diet and Exercise
- Cancer Research: Going the Distance
- Nutrition: Fighting Cancer With Food
- Cancer: Journaling to Save Your Life
- Avastin: A New Hope for Halting Cancer?
- Cancer: Childhood Cancer Survivors
- Leukemia FAQs
- Cancer FAQs
- Cancer Care in the Elderly
- Evolution of Treatment for a Rare Type of Leukemia
- Gleevec and Chronic Myeloid Leukemia
- How Familes Cope with a Leukemia Diagnosis
- Coping with a Bad Disease - Community Counts
- A Family's Leukemia Diary - Coping
- Cancer Survivor?
- Is Multiple Myeloma the Same as Leukemia?
- Can Folic Acid Prevent Leukemia?
- Does Folic Acid Prevent Leukemia?
- What Causes Bone Cancer?
- What Is Bone Cancer?
- Bone Cancer Treatment Options and Their Side Effects
- 10 Cancer Symptoms That Men Ignore
- Chronic Myelogenous Leukemia (CML)
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.